PMID- 35685998
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1178-7015 (Print)
IS  - 1178-7015 (Electronic)
IS  - 1178-7015 (Linking)
VI  - 15
DP  - 2022
TI  - Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A 
      Review on the Emerging Clinical Data.
PG  - 1037-1043
LID - 10.2147/CCID.S267217 [doi]
AB  - Atopic dermatitis (AD) is a chronic inflammatory skin disease that greatly 
      impacts patient quality of life. Type 2 cytokine interleukin (IL)-13 is integral 
      to the pathogenesis of AD. Tralokinumab is a fully human IgG4 monoclonal antibody 
      that specifically targets IL-13, preventing downstream signaling of inflammatory 
      pathways that may contribute to AD. Tralokinumab was US Food and Drug 
      administration (FDA) recently approved for the treatment of moderate to severe AD 
      on December 28, 2021. In our review, we will explore the efficacy and adverse 
      effects (AEs) of tralokinumab for the treatment of patients with moderate to 
      severe AD. A PubMed search for key articles on the emerging clinical data of 
      tralokinumab was performed. Six randomized controlled trials of tralokinumab 
      identified improvements in disease severity measures, including Investigator's 
      Global Assessment (IGA) scores and Eczema Area Severity Index 75 (EASI75) scores. 
      Four of these studies demonstrated improvements in quality of life measures with 
      tralokinumab, including pruritus scores, sleep interference scores, Dermatology 
      Life Quality Index, SCORing Atopic Dermatitis (SCORAD), Patient Oriented Eczema 
      Measure, and The Short Form 36 Health Survey (SF-36v2) scores. One study 
      identified a similar immune response in patients taking tralokinumab to those 
      taking the Tdap and meningococcal vaccines. Upper respiratory infection, 
      conjunctivitis, and headaches were the most common adverse events. The varying 
      criteria to assess changes in AD disease severity across different studies is a 
      limitation of this review. Tralokinumab is another promising biologic option for 
      the treatment of moderate to severe AD, which may reduce disease burden and 
      improve patient quality of life.
CI  - (c) 2022 Kelly et al.
FAU - Kelly, Katherine A
AU  - Kelly KA
AD  - Center for Dermatology Research, Department of Dermatology, Wake Forest School of 
      Medicine, Winston-Salem, NC, USA.
FAU - Perche, Patrick O
AU  - Perche PO
AD  - Center for Dermatology Research, Department of Dermatology, Wake Forest School of 
      Medicine, Winston-Salem, NC, USA.
FAU - Feldman, Steven R
AU  - Feldman SR
AUID- ORCID: 0000-0002-0090-6289
AD  - Center for Dermatology Research, Department of Dermatology, Wake Forest School of 
      Medicine, Winston-Salem, NC, USA.
AD  - Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
AD  - Department of Social Sciences & Health Policy, Wake Forest School of Medicine, 
      Winston-Salem, NC, USA.
AD  - Department of Dermatology, University of Southern Denmark, Odense, Denmark.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220603
PL  - New Zealand
TA  - Clin Cosmet Investig Dermatol
JT  - Clinical, cosmetic and investigational dermatology
JID - 101543449
PMC - PMC9172803
OTO - NOTNLM
OT  - biologic
OT  - biosimilar
OT  - non-medical switching
OT  - real-world data
COIS- Dr. Steven R Feldman has received research, speaking and/or consulting support 
      from Galderma, GSK/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, 
      Celgene, Pfizer, Valeant, AbbVie, Samsung, Janssen, Lilly, Menlo, Merck, 
      Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, 
      Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate and 
      National Psoriasis Foundation. He is founder and majority owner of 
      www.DrScore.com and founder and part owner of Causa Research, a company dedicated 
      to enhancing patients' adherence to treatment. Katherine A Kelly and Patrick O 
      Perche have no conflicts of interest to disclose in this work.
EDAT- 2022/06/11 06:00
MHDA- 2022/06/11 06:01
PMCR- 2022/06/03
CRDT- 2022/06/10 02:39
PHST- 2022/02/19 00:00 [received]
PHST- 2022/05/08 00:00 [accepted]
PHST- 2022/06/10 02:39 [entrez]
PHST- 2022/06/11 06:00 [pubmed]
PHST- 2022/06/11 06:01 [medline]
PHST- 2022/06/03 00:00 [pmc-release]
AID - 267217 [pii]
AID - 10.2147/CCID.S267217 [doi]
PST - epublish
SO  - Clin Cosmet Investig Dermatol. 2022 Jun 3;15:1037-1043. doi: 
      10.2147/CCID.S267217. eCollection 2022.